Latest stories on CSL
Carlisle Companies (CSL) -- Resilience in Sustainable Energy | Guinness Sustainable Energy Q4 2026
GuruFocus63 · neutralearnings
Carlisle Companies (CSL) Declares Quarterly Dividend, Maintains Forward Yield at 1.33%
GuruFocus52 · neutralgeneral
Carlisle Companies Incorporated declares $1.25 dividend
Seeking Alpha56 · neutralgeneral
Carlisle Companies Declares Regular Quarterly Dividend
StockTitan52 · neutralgeneral
Carlisle Price Target Raised To 430 From 425 At Oppenheimer
The Fly63 · neutralanalyst
Carlisle Companies Inc (CSL) Shares Surge 7.6% -- What GF Score of 93 Tells Investors
GuruFocus64 · neutralgeneral
Why is Carlisle (CSL) stock rocketing higher today
Barchart74 · bullishgeneral
Carlisle price target raised to $410 from $402 at Baird
The Fly63 · neutralanalyst
Carlisle (CSL) Q3 2026 Earnings Call Transcript
The Motley Fool58 · neutralearnings
Carlisle expects price/cost parity exiting 2026 while targeting $40 adjusted EPS by 2030
Seeking Alpha63 · neutralearnings
Carlisle Companies Incorporated (CSL) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Carlisle Companies Incorporated 2026 Q3 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Carlisle reports Q3 adjusted EPS $5.92, consensus $5.90
The Fly53 · neutralearnings
Carlisle sees Q4 revenue up high-single-digits
The Fly61 · neutralearnings
Carlisle Companies Incorporated Non-GAAP EPS of $5.92 beats by $0.02, revenue of $1.5B beats by $80M
Seeking Alpha58 · neutralearnings
CARLISLE COMPANIES INC (CSL) files 8-K
SEC 8-K50 · neutralgeneral
Carlisle Companies Reports Third Quarter Results
StockTitan50 · neutralearnings
C.S. Lumber 1Q Net Y203.00M Vs Net Y201.00M
MarketWatch52 · neutralearnings
Carlisle Companies to Announce Third Quarter 2026 Results on October 28, 2026
StockTitan50 · neutralgeneral
Carlisle price target lowered to $402 from $412 at Baird
The Fly38 · neutralanalyst
Carlisle price target lowered to $464 from $475 at Goldman Sachs
The Fly38 · neutralanalyst
CSL strikes $1.55B lixudebart deal with Alentis for rare kidney and liver diseases
Seeking Alpha73 · bullishm&a
CSL to pay up to $1.6 bln to develop rare disease drug; shares rise
Investing.com Markets63 · neutralgeneral